Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Zoledronic acid

Acid sphingomyelinase inhibitor
ALX-430-153-M025 25 mg 112.00 USD
ALX-430-153-M100 100 mg 349.00 USD
ALX-430-153-G001 1 g 784.00 USD
Do you need bulk/larger quantities?
Inhibitor of osteoclastic bone resorption. Prevents osteoporosis and skeletal fractures, particularly in patients with multiple myeloma or prostate cancer. Also used to treat hypercalcemia. Inhibition of acid sphingomyelinase (aSMase) with an IC50 5µm.

Product Details

Alternative Name:1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid, CGP 42446
Formula:C5H10N2O7P2 . H2O
MW:272.1 . 18.0
MI:14: 10187
Purity:≥98% (HPLC)
Appearance:White to off-white powder.
Solubility:Soluble in 0.1N NaOH. Sparingly soluble in water.
Shipping:Ambient Temperature
Long Term Storage:-20°C
Regulatory Status:RUO - Research Use Only
Please mouse over

Product Literature References

Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy: M.A. de Witte, et al.; Biol. Blood Marrow Transplant. 24, 1152 (2018), Abstract; Full Text
Zoledronic Acid Inhibits the Motility of Cancer Stem-like Cells from the Human Breast Cancer Cell Line MDA-MB 231: H. Bühler, et al.; In Vivo 30, 761 (2016), Application(s): Cancer stem-like cells , Abstract;
A Model for Osteonecrosis of the Jaw with Zoledronate Treatment following Repeated Major Trauma: R. N. Howie, et al.; PLoS One 10, e0132520 (2015), Application(s): Injection via rat tail vein, Abstract; Full Text
Potent and Selective Inhibition of Acid Sphingomyelinase by Bisphosphonates.: AG. Roth, et al.; Angew. Chem. Int. Ed. Engl. 48, 7560 (2009), Abstract;
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis: D.M. Black, et al.; New Engl. J. Med. 356, 1809 (2007), Abstract;
Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis: J.J. Body; Expert Opin. Pharmacother. 4, 567 (2003), Abstract;
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma: F. Saad, et al.; J. Natl. Cancer Inst. 94, 1458 (2002), Abstract;
Intravenous zoledronic acid in postmenopausal women with low bone mineral density: I.R. Reid, et al.; New Engl. J. Med. 346, 653 (2002), Abstract;
An enzyme inhibition assay for the quantitative determination of the new bisphosphonate zoledronate in plasma: F. Risser, et al.; J. Pharm. Biomed. Anal. 15, 1877 (1997), Abstract;
Clinical research update: zoledronate: J.J. Body; Cancer 80, 1699 (1997), Abstract; Full Text
Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound: J.R. Green, et al.; J. Bone Miner. Res. 9, 745 (1994), Abstract;

Product Toolbox


Certificate of Analysis


By target:
By biological activity:
Sphingomyelinase Inhibitor
By catalog section:


Technical Service
Customer Service

Related Literature

Product Flyers
Exclusive Sphingosine Kinase 1 Inhibitor
Exclusive Sphingosine Kinase 1 Inhibitor
Download as PDF

All new literature pieces